The PennZone

PHILADELPHIA, Nov. 21, 2023 /PRNewswire/ -- A securities fraud lawsuit has been filed against ACELYRIN, Inc. ("Acelyrin") (NASDAQ: SLRN). The lawsuit is captioned Aramouni v. Acelyrin, Inc., No. 2:23-cv-09672 (C.D. Cal.), and is filed on behalf of purchasers of Acelyrin's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period").

CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT.

Investors who purchased or acquired Acelyrin securities during the Class Period may, no later than January 16, 2024, seek to be appointed as a lead plaintiff representative of the class.

The complaint alleges that, throughout the Class Period, the defendants made failed to disclose that: (i) izokibep was less effective in treating Hidradenitis Suppurativa than defendants had led investors to believe; (ii) accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects; and (iii) as a result, Acelyrin also overstated the company's business prospects post-IPO.

More on The PennZone

• Avery Headley Leads Major Stabilization and Modernization Initiative Across Bronx Affordable Housing Portfolio
• NewReputation's AI Sentiment Analysis Tool Reaches 2,500 Users as Businesses Demand Clearer Brand Intelligence
• CAPO Supply Announces Opening of Second Location in New Castle, Pennsylvania
• $224 Billion Growing Market in Life Settlements Presents Major Opportunity for New Policy Acquisition Business Plan: DLT Resolution Stock Symbol: DLTI
• Fyt-02 Launches on Kickstarter The Smart Sensor That Turns Any Chair Into a Posture & Movement Track

For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at [email protected] or (267) 637-3176, or Andrew Abramowitz at [email protected]  or (215) 875-3015 or CLICK HERE.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

More on The PennZone

• YieldOMega Launches $DOUB Airdrop Campaign Ahead of TimeCurve Launch
• Kaltra Expands Microchannel Water Coil Line for U.S. HVAC Market With New Corrosion-Resistant Tube Technology
• Brewtay Coffee Partners with Alex's Lemonade Stand to Fuel Penn Wynne Volunteers
• White Coat Growth Launches to Help Medical Practices Attract More Patients and Scale with Confidence
• Collectibles EvoRelic Celebrates Stellar 4.8-Star Customer Rating

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts:
James Maro, Senior Counsel
Berger Montague
(267) 637-3176
[email protected]

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]

SOURCE Berger Montague

---

Show All News | Disclaimer | Report Violation